Trade Pfizer ^PFE

Pharmaceutical Stocks To Watch Today - March 31st

Here's Why You Don't Bet Against This Dividend King

Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 - Here's Why

Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry

Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players

Pfizer (NYSE:PFE) Hits New 52-Week High - Should You Buy? - Daily Political

Is It Time To Reconsider Pfizer (PFE) After Diverging Valuation Narratives?

Pfizer (NYSE:PFE) Shares Up 2.6% - Time to Buy?

Announced in June, positive topline results from registratio

Pfizer's (PFE) Shares Up Since Jim Cramer Said "Pass"

Eli Lilly's (LLY) Shares Up Since Jim Cramer Said He Was a Long Term Believer

$1.59 Billion PD-1 Resistant Head and Neck Cancer Market Analysis Report 2026: Size, Growth, and Segmentation Insights to 2030

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million

Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030

Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate

Pfizer (PFE) - Among the 15 Large Cap Stocks with Highest Dividends

Prediction: Buying Pfizer Stock Today Could Set You Up for Life

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Jim Cramer's Hottest GLP-1 and Weight Loss Stock Picks: Top 5 Stocks

Pfizer (NYSE:PFE) Stock Price Down 2% - Here's What Happened

Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Hold" from Analysts

Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samples

Pfizer Oncology Wins Raise Questions On Valuation Gap And Future Revenues

Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program

Top Pharmaceutical Stocks To Watch Today - March 25th - Markets Daily

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026

Exchange Traded Concepts LLC Sells 60,810 Shares of Pfizer Inc. $PFE - Stock Observer

Pfizer (NYSE:PFE) Trading Down 2% - Here's Why

Preliminary Results for the Year Ended 31 December 2025

Jim Cramer on Pfizer: "I Just Need to Know Their Product Flow Better"

Jim Cramer Broke Down 5 Stocks Including Pharma Plays for Rising Oil

Should Pfizer's (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?

Is Pfizer's Late‑Stage Lyme Vaccine Progress Reshaping the Investment Case for PFE?

Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH

Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data

Income Investors Face a Hard Truth About Pfizer's Payout Safety

Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate

Pfizer Inc. $PFE Stock Holdings Increased by Czech National Bank

Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)

Vaccine for Lyme disease one step closer to coming to market - CBS New York

Pfizer (NYSE:PFE) Shares Up 1.2% After Analyst Upgrade

Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA®

This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In

The Iran War Could Make Your Next MRI More Expensive

Pensionfund Sabic Makes New Investment in Pfizer Inc. $PFE - Markets Daily

Top Pharmaceutical Stocks To Watch Today - March 25th - Daily Political

Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - Time to Buy? - Stock Observer

A Look At Pfizer (PFE) Valuation As Shares Trade Near Recent Levels

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Doctors say Lyme disease vaccine trial results 'encouraging' with 70% efficacy shown - Yahoo News Canada

Doctors say Lyme disease vaccine trial results 'encouraging' with 70% efficacy shown - AOL

IP Group - Call Option on Pfizer's Anti-Obesity Program | Investing.com UK

Pfizer Inc. $PFE Shares Bought by SG Americas Securities LLC - Markets Daily

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook

Company Website: https://www.pfizer.com NEW YORK -- (Busin

Pfizer (NYSE:PFE) Price Target Raised to $36.00

Pfizer working for approval on new Lyme disease vaccine as expert says tick activity rising in New England

Pfizer Inc. $PFE Shares Acquired by SG Americas Securities LLC

Park Place Capital Corp Trims Position in Pfizer Inc. $PFE

Organon: A High Cash Yield Hidden Behind Patent Fatigue | Investing.com Canada

Pfizer and Valneva's Lyme Disease Vaccine Demonstrates Over 70% Efficacy in Key Trial, ETPharma

Enhanced dynamic risk stratification of smoldering multiple myeloma

Pfizer working to get approval on new Lyme disease vaccine. Expert says tick activity rising in New England. - CBS Boston

Pfizer says Lyme disease vaccine is holding promise - CBS Boston

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story

Health Care Up, but Not by Much, Amid Cyclical Rotation - Health Care Roundup | Morningstar

Dow Jones Top Company Headlines at 3 PM ET: Danone to Buy Protein-Shake Maker Huel for $1.2 Billion | Toyota ... | Morningstar

Is Pfizer (PFE) Offering Value After Its Post Covid Portfolio Shift And Mixed Returns?

Valneva Shares Plunge 36% Over Lyme Vaccine Phase 3 Data

Valneva (NASDAQ:VALN) Sees Large Volume Increase - Here's Why - Markets Daily

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial | Euronews

Pfizer Lyme disease vaccine fails trial, company to seek FDA approval

Pfizer says long-awaited Lyme vaccine was effective in study

Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l'essai de Phase 3 VALOR

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial | Morningstar

Goodman Financial Corp Purchases 137,772 Shares of Pfizer Inc. $PFE

2 Unpopular Stocks That Should Get More Attention and 1 We Avoid

Pfizer, Valneva post mixed results for Lyme disease vaccine | BioWorld

IP Group PLC (IPZYF) Full Year 2025 Earnings Call Highlights: Strong NAV Growth Amid Market ...

Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis

Tencent: The Premier Hunter of Medical IPOs

Tencent: Der Superjäger für medizinische Börsengänge

Pfizer Inc. $PFE Stock Holdings Increased by Park Avenue Securities LLC

Sound View Wealth Advisors Group LLC Has $1.43 Million Position in Pfizer Inc. $PFE - Daily Political